VIVEON HEALTH ACQ CRP - VHAQ STOCK NEWS

Suneva Medical has launched a new 30 mL iteration of their Amplifine Platelet Rich Plasma (PRP) gel tubes, which have received FDA 510(k) clearance. This larger volume is designed to enhance patient treatment efficiency and accommodate various clinical applications, offering providers a more effective solution in the regenerative aesthetics market. CEO Pat Altavilla emphasized the commitment to delivering high-quality products. The launch comes as part of Suneva's ongoing development strategy in regenerative medicine, following a merger agreement with Viveon Health Acquisition Corp. (NYSE American: VHAQ).

Viveon Health Acquisition Corp. (VHAQ) has made significant progress towards its business combination with Suneva Medical, Inc.. A registration statement on Form S-4 was filed with the SEC on July 13, 2022. The merger is expected to close in the second half of 2022, pending shareholder approval. Suneva reported strong financial performance with $29.5 million in net sales for 2021 and $6.3 million for Q1 2022, indicating robust growth potential in the regenerative aesthetics market.

Suneva Medical has received Canadian regulatory approval for its Dermapose® all-in-one fat sizing syringe, enhancing its presence in the regenerative aesthetics market. Additionally, the U.S. FDA granted 510(k) clearance for the larger 30 mL Amplifine PRP Gel Tube, allowing for greater efficiency in regenerative treatments. These advancements highlight Suneva's commitment to providing innovative, minimally invasive solutions in aesthetic procedures, catering to the growing demand for natural-looking treatment options.

Viveon Health Acquisition Corp. (NYSE American: VHAQ) disclosed in an announcement that its audited financial statements contain a going concern paragraph from its independent auditor. This disclosure complies with NYSE requirements and references the Annual Report on Form 10-K for the year ending December 31, 2021. The company is categorized as a SPAC, targeting potential mergers and acquisitions primarily in the North American healthcare sector. This announcement does not alter its previous financial statements.

Viveon Health Acquisition Corp. (NYSE American: VHAQ) has extended the deadline for its business combination with Suneva Medical, Inc. The new deadline is June 28, 2022, with the possibility of additional monthly extensions until December 28, 2022. This decision, made at the Annual Meeting on March 18, 2022, aims to provide adequate time for completing the merger and filing necessary documents with the SEC. An initial deposit of $720,000 will be placed into the trust account to facilitate this extension.

Viveon Health Acquisition Corp. (NYSE American: VHAQ) announced clarifications regarding its Annual Meeting on March 18, 2022, aimed at extending the merger deadline with Suneva Medical, Inc. The Extension Proposal seeks to push the deadline from March 28 to June 28, 2022, with potential monthly extensions thereafter. A deposit of $720,000 into the trust account is planned if approved, followed by $240,000 month-to-month if additional time is needed. However, redemption and deposit prices per share are uncertain due to unestablished Remaining Public Shares.

Suneva Medical achieved a significant milestone by distributing over 1 million syringes of Bellafill in 2021, a five-year FDA-approved dermal filler. Bellafill, designed for correcting nasolabial folds and acne scars, shows a low adverse event rate of 0.11% in extensive clinical studies. CEO Pat Altavilla highlighted the growing patient demand for longer-lasting fillers like Bellafill, addressing 'filler fatigue.' An announced merger with Viveon Health Acquisition Corp. (NYSE: VHAQ) is set to bolster growth and market presence.

Suneva Medical announced FDA acceptance of updates to the Plasma IQ label, notably removing the eye contraindication, enhancing treatment options around the eye. This update supports the company’s merger with Viveon Health Acquisition Corp. (VHAQ), aiming for increased market access. Plasma IQ is the first handheld FDA-cleared plasma energy device for skin lesion treatment. The merger is set to allow shares to trade under the symbol RNEW upon completion. Suneva, located in San Diego, continues to innovate in regenerative aesthetics, focusing on patient solutions.

Brodsky & Smith has initiated investigations concerning Zogenix, Inc. (ZGNX), Social Capital Suvretta Holdings Corp. III (DNAC), and Viveon Health Acquisition Corp. (VHAQ) due to potential breaches of fiduciary duties by their boards during acquisition agreements. Zogenix is proposed to be acquired by UCB for $26.00 per share, plus a $2.00 CVR. Social Capital's merger with ProKidney results in a 9% ownership for its shareholders. Viveon Health's merger with Suneva Medical will leave its shareholders with 39.3% ownership. These investigations assess fairness in the acquisition processes.